| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe |
NCT00963768: A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 116 | US, Europe, RoW | JNJ 28431754, Canagliflozin, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | 12/07 | 12/07 | | |
NCT01177163: A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 29 | US | Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | | 03/09 | | |
|
NCT01128985: A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 39 | US | Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | | 07/10 | | |
|
NCT01273558: A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 28 | Europe | Canagliflozin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | | 07/11 | | |
NCT01381887: A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 37 | US | Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | 11/11 | 11/11 | | |
NCT01483781: A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 36 | Europe | Canagliflozin, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2, Plasma Volume | 08/12 | 08/12 | | |
NCT01512849: A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment |
|
|
| Completed | 1 | 24 | Japan | TA-7284 Low, TA-7284 High | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 09/12 | 09/12 | | |
NCT02000700 / 2013-005455-32: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 17 | US, RoW | Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 04/16 | 04/16 | | |
NCT02009488: Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) |
|
|
| Completed | 1 | 59 | US | Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 01/17 | 01/17 | | |
